A review of the efficacy and safety of oral antidiabetic drugs

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2013-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.2013.752813PMID 23241069PMCID PMC3977601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  2012cited by this paper
• An unusual initial manifestation of acute leukemia.

  2012cited by this paper
• 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

  2012influential reference
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient

  2012cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

  2012cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin

  2012cited by this paper
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

  2012influential reference
• Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

  2012cited by this paper
• Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus

  2012cited by this paper
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

  2012cited by this paper
• Elevated uric acid increases the risk for acute kidney injury.

  2012cited by this paper
• Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications.

  2012cited by this paper
• Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Saxagliptin

  2012cited by this paper
• Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double‐blind, non‐inferiority trial

  2011influential reference
• Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations

  2011cited by this paper
• Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men

  2011cited by this paper
• Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes

  2011cited by this paper
• Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

  2011cited by this paper
• Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

  2011cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial

  2011influential reference
• Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

  2011cited by this paper
• Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

  2011cited by this paper
• Long‐term treatment with the dipeptidyl peptidase‐4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52‐week efficacy and safety study

  2011cited by this paper
• Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load.

  2011cited by this paper
• The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

  2011cited by this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cited by this paper
• Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise

  2010cited by this paper
• Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

  2010cited by this paper
• Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.

  2010cited by this paper
• Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

  2010cited by this paper
• Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1.

  2010cited by this paper
• A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

  2010cited by this paper
• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  2010cited by this paper
• Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

  2010cited by this paper
• Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo‐Controlled Clinical Study

  2010cited by this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

  2010cited by this paper
• Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

  2010cited by this paper
• Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

  2010influential reference
• Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide

  2010cited by this paper
• Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population

  2010cited by this paper
• Radiation Protection Dosimetry. Preface.

  2010cited by this paper
• Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study

  2010influential reference
• SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy.

  2010cited by this paper
• Trends in diabetes treatment in Canadians, 1994-2004.

  2010cited by this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cited by this paper
• Effect of nateglinide on the incidence of diabetes and cardiovascular events.

  2010cited by this paper
• Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations.

  2010cited by this paper
• Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

  2010cited by this paper
• Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.

  2009cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.

  2009cited by this paper
• A Review of Bile Acid Sequestrants: Potential Mechanism(s) for Glucose-Lowering Effects in Type 2 Diabetes Mellitus

  2009cited by this paper
• Colesevelam Hydrochloride and Lanthanum Carbonate Interfere with the Absorption of Levothyroxine

  2009cited by this paper
• Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes

  2009influential reference
• A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers

  2009cited by this paper
• Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

  2009cited by this paper
• Repaglinide induced acute hepototoxicity.

  2009cited by this paper
• Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

  2008cited by this paper
• Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride

  2008cited by this paper
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

  2008cited by this paper
• Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

  2008cited by this paper
• Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

  2008cited by this paper
• Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy.

  2008cited by this paper
• Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

  2008cited by this paper
• Rosiglitazone-Associated Fractures in Type 2 Diabetes

  2008cited by this paper
• Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy

  2008cited by this paper
• Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event

  2008cited by this paper
• Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

  2008cited by this paper
• Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naïve elderly patients with type 2 diabetes

  2008cited by this paper
• Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects.

  2008cited by this paper
• Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007influential reference
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Cholestatic hepatitis associated with repaglinide.

  2005cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Alpha-glucosidase inhibitors for type 2 diabetes mellitus.

  2005cited by this paper
• Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

  2005cited by this paper
• Drug-Induced Pancreatitis: An Update

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

  2005cited by this paper
• Does Bromocriptine Improve Glycemic Control of Obese Type-2 Diabetics?

  2004cited by this paper
• Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

  2004cited by this paper
• Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone.

  2004cited by this paper
• Acute hepatotoxicity caused by repaglinide.

  2004cited by this paper
• The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.

  2004cited by this paper
• Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide

  2003cited by this paper

• In Vivo , Ex Vivo , and In Vitro Antihyperglycemic Evaluation of Croton ehrenbergii

  2025cites this paper
• Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system

  2025cites this paper
• Exploring the Anti-Diabetic Potential of Conocarpus lancifolius Phytochemicals: Insights from Molecular Docking, MD Simulations, and MMGBSA Studies

  2025cites this paper
• Enhanced Bioactivity of Fermented Aralia cordata Extract for Glucose and Immune Modulation

  2025cites this paper
• Holistic investigation of Cotula cinerea essential oil against diabetes: hypoglycemic activity, enzymatic inhibition, GC-MS characterization, ADMET forecasting, MD simulations, and DFT insights

  2025cites this paper
• Antidiabetic Potential of Mentha piperita Essential Oil: GC-MS Profiling, in Vitro, in Vivo and in Silico Analyses

  2025cites this paper
• Review on conventional as well herbal approach for treatment of diabetes mellitus

  2025cites this paper
• Effect of Anti-Diabetic Medication Use on Sepsis Risk in Type 2 Diabetes Mellitus: A Multivariate Analysis

  2025cites this paper
• Mechanisms of gypenosides in type 2 diabetes mellitus via regulation of m6A methylase METTL3/14 and demethylase FTO.

  2025cites this paper
• Influence of drying on the nutritional composition, phytochemical constituents and in vitro antioxidant properties of Cymbopogon citratus (lemongrass) teas

  2025cites this paper
• Glucosinolates Hydrolysis Products: Promising Bioactives for the Prevention of Diabetes

  2025cites this paper
• Machine learning and molecular dynamics simulations predict potential TGR5 agonists for type 2 diabetes treatment

  2025cites this paper
• Antidiabetic Potential of Sea Urchin Tripneustes gratilla Nanosuspension Based on In Vitro Enzyme Inhibition, In Vivo Evaluation, and Chemical Profiling Approaches

  2025cites this paper
• A glucose-responsive alginate-based hydrogel laden with modified GLP-1 and telmisartan ameliorates type 2 diabetes and reduces liver and kidney toxicities.

  2025cites this paper
• Nano-Based Drug Delivery Systems for Managing Diabetes: Recent Advances and Future Prospects

  2025cites this paper
• Hybrid Derivatives of 1,3-Diphenyl-1H-Pyrazole and L-α-Amino Acids: Synthesis, Biological Evaluation, and Molecular Docking Studies

  2025cites this paper
• Comparative Pharmacological and Pharmaceutical Perspectives on Antidiabetic Therapies in Humans, Dogs, and Cats

  2025cites this paper
• HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment

  2025cites this paper
• Optimization of Indole- and Pyrazole-fused Glycyrrhetinic Acid Derivatives as Potent PTP1B Inhibitors: In Silico, In Vitro, In Vivo, and Metabolomic Studies.

  2025cites this paper
• A bibliometric study and visualization of the current state of research on DPP-4 inhibitors for the treatment of diabetes mellitus

  2024cites this paper
• Discerning computational, in vitro and in vivo investigations of self-assembling empagliflozin polymeric micelles in type-2 diabetes

  2024cites this paper
• Systems Biology of Human Microbiome for the Prediction of Personal Glycaemic Response

  2024cites this paper
• Berberine hydrochloride-loaded lipid-based nanoparticles ameliorate β-cell function by targeting Nrf2/NF-κB signaling pathway in alloxan-induced diabetes using a murine model: Optimization through full factorial design

  2024cites this paper
• Effects of Coadministration of Eryngium billardieri and Boswellia serrata Extracts on Insulin-Related Biomarkers, Lipid Profile, and Hepatic Enzymes in Patients with Type 2 Diabetes: A Randomized Controlled Clinical Trial

  2024cites this paper
• Exploring the Potential of Epigallocatechin Gallate in Combating Insulin Resistance and Diabetes

  2024cites this paper
• Brain glucose metabolism: Role of nitric oxide.

  2024cites this paper
• Anti-obesity and anti-diabetic effects of L-citrulline are sex-dependent.

  2024cites this paper
• Effect of Different Fractions of Lawsonia inermis Linn on Haematobiochemical Changes, Osmotic Fragility and Lipid Profile in Streptozotocin-induced Diabetic Wistar Rats

  2024cites this paper
• Exploring the DPP IV inhibitory potential: molecular docking and dynamic simulations of pyridine-3-carboxylic acid and pyrrolidine-2-carboxylic acid analogs

  2024cites this paper
• Metformin in Antiviral Therapy: Evidence and Perspectives

  2024cites this paper
• Blue mussel (Mytilus edulis) water extract ameliorates intestinal immune response in high-fat diet-streptozotocin-induced diabetic mice.

  2024cites this paper
• In silico exploration of the potential inhibitory activities of in-house and ZINC database lead compounds against alpha-glucosidase using structure-based virtual screening and molecular dynamics simulation approach

  2024cites this paper
• Designing combinational herbal drugs based on target space analysis

  2024cites this paper
• One-pot domino synthesis of 1H-isochromene and pyran carbonitrile from pyrazole aldehyde derivatives as potential anti-diabetic and antioxidant targets

  2024cites this paper
• A Case of Acromegaly With Progressed Diabetic Retinopathy and Sarcopenia Diagnosed Following the Onset of Severe Hypoglycemia

  2024cites this paper
• Role of Phytoconstituents of Medicinal Plants in Curing Type 2 Diabetes

  2024cites this paper
• Elucidating the chemical profile and biological studies of Verbascum diversifolium Hochst. extracts

  2024cites this paper
• Recent Developments in Drug Design of Oral Synthetic Free Fatty Acid Receptor 1 Agonists

  2024cites this paper
• Animal Models for Understanding the Mechanisms of Beta Cell Death during Type 2 Diabetes Pathogenesis

  2024cites this paper
• Circular RNA PIP5K1A Promotes Glucose and Lipid Metabolism Disorders and Inflammation in Type 2 Diabetes Mellitus

  2023cites this paper
• Analysis of anti-diabetic property of Aloe vera (L.) Burm.f. by in silico molecular docking

  2023cites this paper
• In-silico Study of an Ethnobotanical Plant; Urtica dioica for Assessing Anti-diabetic Potential

  2023cites this paper
• In-silico Study of Phytochemicals of Ethnobotanical Plant Cannabis sativa for Anti-Diabetic Potential

  2023cites this paper
• Potential of Clinacanthus Nutans as an Alternative Therapeutic Agent for Diabetes Mellitus

  2023influential citation
• Medicinal Chemistry of Non-peptidomimetic Dipeptidyl Peptidase IV (DPP IV) Inhibitors for Treatment of Type-2 Diabetes Mellitus: Insights on Recent Development

  2023cites this paper
• Protective effects and mechanisms of opuntia polysaccharide in animal models of diabetes mellitus: A systematic review and meta-analysis.

  2023cites this paper
• Interlinking of diabetes mellitus and cancer: An overview

  2023cites this paper
• Development of UV-Visible spectrophotometric method for the estimation of vildagliptin in different medium

  2023cites this paper
• Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study

  2023cites this paper
• Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches

  2022cites this paper
• Comparison of Three Different Glucose-lowering Drugs on Serum Levels of Glucose and Pancreas Histopathology in Streptozotocin-Induced Diabetic Rats

  2022cites this paper
• α-Glucosidase Inhibitory Activity and Anti-Adipogenic Effect of Compounds from Dendrobium delacourii

  2022cites this paper
• In silico identification of potential inhibitors from rumex vesicarius against DPP4 of diabetes mellitus

  2022cites this paper
• The Roles of Probiotics in the Gut Microbiota Composition and Metabolic Outcomes in Asymptomatic Post-Gestational Diabetes Women: A Randomized Controlled Trial

  2022cites this paper
• Minor iridoid glycosides from the fruits of Cornus officinalis Sieb. et Zucc. and their anti-diabetic bioactivities.

  2022cites this paper
• MONOFLORAL BRASSICA NIGRA POLLEN IMPROVES OXIDATIVE STRESS AND METABOLIC PARAMETERS IN STREPTOZOTOCIN-INDUCED DIABETIC RATS

  2022cites this paper
• Diyabetik sıçanlarda Vaccinium myrtillus'un paraoksonaz aktivitesi, bazı biyokimyasal parametreler ve pankreas fonksiyonları üzerine koruyucu etkisi.

  2022cites this paper
• Controlled release of metformin-loaded sa/peg scaffolds produced by 3D-printing technology

  2022cites this paper
• Icariside II Exerts Anti-Type 2 Diabetic Effect by Targeting PPARα/γ: Involvement of ROS/NF-κB/IRS1 Signaling Pathway

  2022cites this paper
• Ferulic acid improves glucose homeostasis by modulation of key diabetogenic activities and restoration of pancreatic architecture in diabetic rats

  2022cites this paper
• Preparation, physical characterization, pharmacokinetics and anti-hyperglycemic activity of esculetin-loaded mixed micelles.

  2022cites this paper
• Molecular Docking and Dynamics Simulation of Natural Compounds from Betel Leaves (Piper betle L.) for Investigating the Potential Inhibition of Alpha-Amylase and Alpha-Glucosidase of Type 2 Diabetes

  2022cites this paper
• Effect of formulation variables on the characteristics of vildagliptin microspheres

  2022cites this paper
• In vitro α-glucosidase inhibitory activity of medicinal plants used traditionally for treating diabetes in Vhembe District, South Africa

  2022cites this paper
• A retrospective observational study

  2022cites this paper
• In silico proteolysis and molecular interaction of tilapia (Oreochromis niloticus) skin collagen-derived peptides for environmental remediation.

  2022cites this paper
• Biochemical and tissue physiopathological evaluation of the preclinical efficacy of Solanum torvum Swartz leaves for treating oxidative impairment in rats administered a β-cell-toxicant (STZ).

  2022cites this paper
• Hypoglycemic and hypolipidemic effects of sugar beet (Beta vulgaris L.) extract on C57BL/KsJ db/db mice

  2022cites this paper
• Antioxidant, Hypoglycemic and Molecular Docking Studies of Methanolic Extract, Fractions and Isolated Compounds from Aerial Parts of Cymbopogon citratus (DC.) Stapf

  2022cites this paper
• Therapeutic efficacy of Clompanus pubescens leaves fractions via downregulation of neuronal cholinesterases/Na+-K+ATPase/IL-1 β, and improving the neurocognitive and antioxidants status of streptozotocin-induced diabetic rats.

  2022cites this paper
• Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study

  2021cites this paper
• The effect of cumin (Cuminum cyminum L.) supplementation on glycemic indices: A systematic review and meta‐analysis of randomized controlled trials

  2021cites this paper
• FFAR1/GPR40: one target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.

  2021cites this paper
• Postprandial glucose-lowering effect of cagaita (Eugenia dysenterica DC) fruit juice in dysglycemic subjects with metabolic syndrome: An exploratory study.

  2021cites this paper
• Hydroalcoholic Extract of Solanum lycocarpum A. St. Hil. (Solanaceae) Leaves Improves Alloxan-Induced Diabetes Complications in Mice.

  2021cites this paper
• Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.

  2021cites this paper
• Efficacy and safety of Shenqi Jiangtang Granules plus oral hypoglycemic agent in patients with type 2 diabetes mellitus

  2021cites this paper
• Amelioration of related complications by the combined usage of Gymnadenia orchidis Lindl and pumpkin seed in type 2 diabetic mice

  2021cites this paper
• HYPOGLYCEMIC ACTIVITY OF ETHYL ACETATE FRACTION COMBINATION OF MORINDA FRUIT AND CINNAMON BARK USING GLUCOSE-INDUCED IN MICE

  2021cites this paper
• Potential Antidiabetic Effects of Seaweed Extracts by Upregulating Glucose Utilization and Alleviating Inflammation in C2C12 Myotubes

  2021cites this paper
• Targeting mangiferin loaded N-succinyl chitosan-alginate grafted nanoparticles against atherosclerosis - A case study against diabetes mediated hyperlipidemia in rat.

  2021cites this paper
• Drug Resistance in Diabetes

  2021cites this paper
• Beneficial actions of esculentin-2CHa(GA30) on high sucrose-induced oxidative stress in Drosophila melanogaster.

  2021cites this paper
• Progress in the Medicinal Value, Bioactive Compounds, and Pharmacological Activities of Gynostemma pentaphyllum

  2021cites this paper
• SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.

  2021cites this paper
• Discovery of Novel G‐Protein‐Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 2 Diabetes

  2021cites this paper
• Effects of BTI320 on Glycemic Control in Patients with Type 2 Diabetes

  2021cites this paper
• Strategies for the delivery of antidiabetic drugs via intranasal route.

  2021cites this paper
• Discovery of Orally Bioavailable Purine-Based Inhibitors of the Low-Molecular-Weight Protein Tyrosine Phosphatase.

  2021cites this paper
• Identifying Potential High-Risk Medication Errors Using Telepharmacy and a Web-Based Survey Tool

  2021influential citation
• Effect of hydroxychloroquine on glucose control in patients with and without diabetes: a systematic review and meta-analysis of randomized controlled clinical trials

  2021cites this paper
• Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein–Coupled Receptor 5

  2021cites this paper
• Rational Design of Novel Inhibitors of α-Glucosidase: An Application of Quantitative Structure Activity Relationship and Structure-Based Virtual Screening

  2021cites this paper
• Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta-analysis

  2021cites this paper
• Discovery and evaluation of novel benzazepinone derivatives as glycogen phosphorylase inhibitors with potent activity.

  2021cites this paper
• In silico identification of antidiabetic target for phytochemicals of A. marmelos and mechanistic insights by molecular dynamics simulations

  2021cites this paper
• Drug Therapies Affecting Renal Function: An Overview

  2021cites this paper
• Bioequivalence of a Generic Nateglinide Formulation in Healthy Chinese Volunteers under Fasting and Fed Conditions: A Randomized, Open-Label, Double-Cycle, Double-Crossover Study

  2021cites this paper
• A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice.

  2020cites this paper
• A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.

  2020cites this paper